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The signal hypothesis showed
the intracellular location of
proteins is dictated by 
targeting information within a
protein’s sequence (Blobel,
2000) and holds true for
protein targeting to all sub-
cellular locations (Schatz and
Dobberstein, 1996). The effi-
ciency and fidelity of protein
targeting pathways are
exquisite, provided the target-
ing sequence is openly dis-
played during, or very soon
after, synthesis of the protein.
It is now becoming
apparent that protein target-
ing, like so many intracellu-
lar processes, is subject to
regulation. Proteins in transit
to their intended intracellular
destination can be hijacked
and sequestered in a distinct
subcellular compartment. In
the cases we know of so far,
only in response to a specif-
ic signal is the protein liber-
ated to find its way to its site
of action within the cell. The
report in this issue of Cancer
Cell by Kufe and coworkers
on the intracellular portion of
MUC1 (Ren et al., 2004)
suggests it might join the list
of protein hijack victims that
include apoptosis regulators
of the Bcl-2 family (Bim and
Bmf) and transcriptional
activators SREBP and NF-
κB (Figure 1).
Normal cellular home-
ostasis is maintained by a bal-
ance in cell proliferation and
apoptosis; disturbances in this
balance directly contribute to
cancer. Members of the Bcl-2
family of proteins are key regu-
lators of apoptosis, and most
of them carry C-terminal
hydrophobic sequences capa-
ble of targeting them to 
membranes. However, some
pro-apoptotic family mem-
bers, such as Bim and Bmf,
are sequestered away from
their site of action at the mito-
chondrial outer membrane
through interactions with
cytoskeletal proteins: Bim with
the microtubular dynein motor
and Bmf with the myosin V
motor (Puthalakath et al.,
1999, 2001). Damage signals
trigger their release and rapid
translocation to the mitochon-
drial surface, where Bim and
Bmf neutralize the prosurvival
activity of other Bcl-2 family
members, precipitating cell
death.
The active forms of NF-
κB and SREBP are potent
transcriptional activators: NF-
κB activates genes that regu-
late immune responses, cell
division, and programmed
cell death, whereas SREBP
activates genes encoding
enzymes of the cholesterol
and fatty acid biosynthetic
pathways. Each protein has a
localization signal that could
mediate targeting to the
nucleus. However, newly
translated NF-κB is hijacked
in the cytoplasm by an inter-
action with the IκB family of
repressor proteins. The IκB
proteins act by covering the
nuclear localization signal
within NF-κB, thereby
preventing its recognition
(Ghosh and Karin, 2002).
Exposure of cells to extracel-
lular stimuli, such as ionizing
radiation or cytokines, results
in IκB-kinase activation, with
subsequent phosphorylation
and proteolysis of the IκB
captor. This exposes the
nuclear localization sequence
of NF-κB and allows its entry
into the nucleus to transacti-
vate the expression of target
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Protein hijacking: Key proteins held captive against their will
Proteins travel to their appropriate intracellular homes by means of the targeting signals they carry. It now seems that a
short, but important, list of key regulatory proteins are victims of protein hijacking: Bid, Bim, NF-κB, SREBP, and perhaps
the intracellular portion of MUC1.These provide critical functions within a particular subcellular compartment, but are ini-
tially prevented from finding their way to this intracellular home. Only in response to specific physiological signals are
these proteins released to find the site at which they act.
Figure 1. Release of hijacked proteins
A: Prior to external stimuli being applied, Bim and Bmf are held as
components of cytoskeletal motor complexes, the NF-κB:IκB complex
is cytosolic, SREBP is integrated and maintained in the endoplasmic
reticulum, and the C-ter domain of MUC1 is associated with the heav-
ily glycosylated N-ter domain at the cell surface. Some C-ter domain
of MUC1 might also be associated with mitochondria. 
B: After appropriate stimulation, Bim and Bmf can be released to tar-
get mitochondria, NF-κB released to the nucleus, and SREBP released
for transit via the Golgi and final release for translocation into the
nucleus. By some means, either retrograde translocation from the
endoplasmic reticulum (shown), release from the plasma membrane,
or expression from a novel variant mRNA, the C-ter domain of MUC1 is
targeted to mitochondria.
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genes. The importance of proper regula-
tion of NF-κB activity for normal cellular
physiology is underscored by the fact that
constitutively active nuclear NF-κB, often
due to hyperinduction of the NF-κB acti-
vation pathway and in some instances
defective IκB activity or levels, con-
tributes to the development and malig-
nancy of numerous human carcinomas
(Karin et al., 2002).
An even more complex scenario
sequesters SREBP from the nucleus
(Yang et al., 2002). The activation
domain of SREBP is linked to a signal
sequence that targets the protein to be
cotranslationally integrated into the
endoplasmic reticulum, where it interacts
with a sterol-sensing protein, SCAP.
SCAP collaborates with a retention fac-
tor to hold the SREBP-SCAP complex in
the endoplasmic reticulum. When sterol
levels in the cell are low, the retention
factor releases SREBP-SCAP to escape
to the Golgi, where proteolytic process-
ing releases the activation domain of
SREBP, which enters the nucleus to
exert its function in activation of gene
expression.
MUC1 is a cell surface oncoprotein,
normally expressed on secretory epithe-
lial cells and highly overexpressed in
several human carcinomas. It is synthe-
sized as a single polypeptide with a sig-
nal sequence that sends the protein 
into the endoplasmic reticulum. After
processing to an N-ter extracellular
fragment and C-ter transmembrane frag-
ment, glycosylation of the extracellular
domain allows MUC1 transport to the
cell surface (Figure 1). Ren et al. show
that treatment of cells with heregulin, a
growth factor that signals via the ErbB
pathway, induces mitochondrial targeting
of MUC1 C-ter. Expression of MUC1
inhibits activation of apoptosis by 
genotoxic agents, and therefore, the con-
sequence of sending MUC1 to mitochon-
dria might be to inhibit the prodeath
activity of other mitochondrial proteins.
As proposed, this could be physiological-
ly crucial: damage to the epithelium
causes activation of the heregulin/ErbB
pathway, inducing cell division for an
effective replacement of damaged cells.
Concomitant targeting of MUC1 C-ter to
mitochondria might attenuate apoptosis
during this stress response. Inhibition of
apoptosis by MUC1 could have an
important implication in its function in
tumor physiology: constitutive mitochon-
drial localization of MUC1 C-ter
observed in cancer cell lines (see below)
might protect carcinomas from the apo-
ptotic response following treatment with
genotoxic agents.
So how and when is MUC1 C-ter tar-
geted to mitochondria? MUC1 C-ter
might go to mitochondria constitutively,
since Ren et al. observe it to some extent
as mitochondrial even in the absence of
heregulin treatment. If this proves to be
the case, MUC1 could be yet another
example of proteins directly targeted to
dual locations, with similar or different
functions in each compartment (Silva-
Filho, 2003). However, the heregulin-
independent mitochondrial localization
may be a result of either a more active
ErbB pathway or higher MUC1 expres-
sion levels in cancer cell lines. MUC1
could then be another hijacked protein,
restricted from mitochondria prior to a
physiological signal.
How mitochondrial targeting of
MUC1 C-ter is achieved is currently not
clear, but there are several possibilities. It
could be released directly from the plas-
ma membrane, expressed from an alter-
native mRNA, or retargeted at the level of
the endoplasmic reticulum. Retargeting
from the endoplasmic reticulum could be
a consequence of activation of a MAP
kinase pathway caused by binding of
heregulin to the ErbB receptor, since 
it signals the unfolded polypeptide
response and cessation of glycosylation
that would lead to retrograde transloca-
tion of proteins like MUC1 C-ter. The
newly liberated C-ter fragment would be
in the cytosol, but with an exposed
hydrophobic (formerly transmembrane
segment) available for binding to molecu-
lar chaperones that deliver unfolded pro-
teins to mitochondria (Voos, 2003).
Far from some diabolical intent, it
seems the hijackers and their captive
proteins serve as sensors for specific
stimuli. Since protein targeting is a rapid
process that can be completed in the
absence of ongoing transcription or
translation, the targeting information in
the hijacked protein enables a response
to stimuli that might shut down other cel-
lular activities. In the case of MUC1 C-ter
targeting, interesting questions are now
raised over how and from where the pro-
tein is liberated, what exactly it does
once targeted to mitochondria, and
whether it acts at the surface or from
deep within the organelle. The work by
Ren et al. on the function of MUC1 in
resistance to genotoxic agents sets the
stage for a wealth of further knowledge.
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